Alpha Biopharma is a technology company.
晨泰医药::专注于创新药物从临床研发到商业化运作成功。作为一家具有全球视野的制药企业，晨泰医药获得国内外多家知名基金的支持，致力于开发临床急需的创新治疗药物。
Alpha Biopharma has raised $86.0M across 3 funding rounds.
Alpha Biopharma has raised $86.0M in total across 3 funding rounds.
Alpha Biopharma has raised $86.0M in total across 3 funding rounds.
Alpha Biopharma's investors include Qiming Venture Partners.
Alpha Biopharma is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative drugs, primarily targeting unmet medical needs in oncology. Its lead product, Zorifertinib, is a next-generation EGFR tyrosine kinase inhibitor (TKI) designed for treating EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) patients with central nervous system metastases, notable for its 100% blood-brain barrier penetration. The company also expands its pipeline through partnerships, such as an exclusive collaboration with Wugen Inc. to develop universal "off-the-shelf" Memory NK and CAR-T cell therapies for various cancers. Alpha Biopharma serves patients with advanced cancers and aims to address critical gaps in cancer treatment, demonstrating strong growth momentum supported by national projects and international collaborations[1][3][4].
Founded in 2017, Alpha Biopharma was established by a team with expertise in medical, clinical operations, regulatory affairs, and commercialization. The idea emerged from a commitment to innovate in drug development with a global vision, supported by both domestic and international funds. Early recognition includes being named a "Potential Unicorn Enterprise" in China and receiving national funding as part of the Major Project for New Drug Innovation, marking pivotal milestones in its clinical and commercial progress[1][2][5].
Alpha Biopharma rides the global trend of precision oncology and immunotherapy, focusing on targeted therapies and cell-based treatments that are transforming cancer care. The timing is critical as advances in molecular biology and immuno-oncology create opportunities for novel therapies addressing previously unmet clinical needs, especially in CNS metastases and solid tumors. Market forces such as increasing cancer incidence, demand for personalized medicine, and supportive regulatory environments favor Alpha Biopharma’s growth. Its collaborations and innovative pipeline contribute to the broader ecosystem by advancing next-generation therapies and fostering international pharmaceutical partnerships[1][4].
Looking ahead, Alpha Biopharma is poised to advance its lead and pipeline candidates through clinical trials toward commercialization, potentially expanding its global footprint. Trends in immuno-oncology, cell therapy, and precision medicine will shape its trajectory, with increasing emphasis on off-the-shelf cell therapies and CNS-penetrant drugs. Its influence may grow as it leverages strategic partnerships and national support to become a global leader in innovative cancer therapeutics, continuing to address critical unmet needs in oncology and immunotherapy[1][4].
Alpha Biopharma has raised $86.0M across 3 funding rounds. Most recently, it raised $24.0M Series B in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $24.0M Series B | Qiming Venture Partners | |
| Apr 1, 2021 | $25.0M Series B | Qiming Venture Partners | |
| Jun 1, 2018 | $37.0M Series A | Qiming Venture Partners |